<DOC>
	<DOC>NCT02654899</DOC>
	<brief_summary>The current study is the first clinical trial proposed with PF-06815345. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single oral doses of PF-06815345 to healthy adult subjects.</brief_summary>
	<brief_title>Single Dose Study of PF-06815345 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Healthy males and female of nonchildbearing potential; Age of 1855, inclusive; Body Mass Index 17.534.9 kg/m2, inclusive; Body weight &gt;50 kg; Not on any prescription or nonprescription drugs within 7 days or 5 halflives prior to first dose. Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Healthy subjects</keyword>
	<keyword>Single Ascending Dose</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>